Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/27/2026

1. ON
2. SYNA
3. SPY
4. MU
5. AAPL
6. VEON
7. DRI
8. RKLB
9. SPCX
10. NKE

Go back to Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

BTIG Upgrades Mersana (MRSN) to Buy

February 28, 2024 3:38 PM EST

BTIG analyst Kaveri Pohlman upgraded Mersana (NASDAQ: MRSN) from Neutral to Buy with a price target of $6.00.

The analyst comments "We believe that the upcoming catalysts this year could significantly de-risk the Dolasynthen platform and the lead ADC, XMT-1660 (B7-H4 Dolalock ADC),... More